NFL Biosciences SA (EPA:ALNFL)
France · Delayed Price · Currency is EUR 0.5260
-0.0340 (-6.07%)
Oct 23, 2026, 10:58 AM CEST
NFL Biosciences Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | 0 | 0 | 0 | 0.2 | 0 | 0 |
| 0 | 0 | 0 | 0.2 | 0 | 0 | |
Revenue Growth | 1817.68% | 308.70% | -99.98% | 909040.91% | -43.59% | 1200.00% |
Cost of Revenue | 2.52 | 2.52 | 1.55 | 3.48 | 2.24 | 0.53 |
Gross Profit | -2.52 | -2.52 | -1.55 | -3.28 | -2.24 | -0.53 |
Selling, General & Admin | 1.18 | 1.18 | 1.07 | 0.78 | 0.72 | 0.28 |
Other Operating Expenses | -0.05 | 0.08 | 0.11 | 0.12 | 0.07 | 0.05 |
Operating Expenses | 1.22 | 1.35 | 1.24 | 0.95 | 0.85 | 0.37 |
Operating Income | -3.74 | -3.87 | -2.79 | -4.23 | -3.08 | -0.9 |
Interest Expense | -0.01 | -0.01 | -0 | -0.01 | -0 | -0 |
Interest & Investment Income | 0.03 | 0.03 | 0.07 | 0.09 | - | 0 |
Currency Exchange Gain (Loss) | -0 | -0 | -0 | -0 | 0 | - |
Other Non Operating Income (Expenses) | 0.29 | - | 0.01 | 0.03 | 0.18 | -0.22 |
EBT Excluding Unusual Items | -3.43 | -3.86 | -2.72 | -4.11 | -2.9 | -1.12 |
Other Unusual Items | - | - | - | - | 0.04 | - |
Pretax Income | -3.43 | -3.86 | -2.72 | -4.11 | -2.86 | -1.12 |
Income Tax Expense | -0.39 | -0.54 | -0.64 | -0.37 | -0.42 | -0.14 |
Net Income | -3.04 | -3.32 | -2.08 | -3.75 | -2.44 | -0.98 |
Net Income to Common | -3.04 | -3.32 | -2.08 | -3.75 | -2.44 | -0.98 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | - | 13 | 10 | 8 | 5 | 5 |
Shares Outstanding (Diluted) | - | 13 | 10 | 8 | 5 | 5 |
Shares Change | - | 28.81% | 23.79% | 55.89% | - | - |
EPS (Basic) | - | -0.26 | -0.21 | -0.46 | -0.47 | -0.19 |
EPS (Diluted) | - | -0.26 | -0.21 | -0.46 | -0.47 | -0.19 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Margin | -118911.42% | -2059909.04% | -6065415.22% | -2115.09% | -14014404.54% | -2312479.49% |
Profit Margin | -96693.58% | -1764876.06% | -4523563.04% | -1872.63% | -11106745.46% | -2508315.38% |
EBITDA | - | -3.79 | -2.72 | -4.17 | -3.03 | -0.86 |
D&A For EBITDA | - | 0.09 | 0.07 | 0.06 | 0.05 | 0.04 |
EBIT | -3.74 | -3.87 | -2.79 | -4.23 | -3.08 | -0.9 |
Revenue as Reported | 0 | 0 | 0 | 0.2 | 0 | 0 |